Deal Watch: AbbVie, arGEN-X To Explore Immuno-Oncology According To GARP
Also during a busy two-week stretch, AbbVie signs a partnership to co-develop drug conjugate products with CytomX, acquires privately held Stemcentrx, and agrees to a broad-based five-year cancer research collaboration with University of Chicago. Sanofi makes formal bid to acquire Medivation, which is rejected.
You may also be interested in...
UroGen, Biohaven and Ovid bring the year's US biopharma IPO count to 11 as returns remain in mostly positive territory. Ovid is one of only two newly public drug developers trading below its offering price.
The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.